These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 9324177)

  • 21. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
    Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
    Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of 5-fluorouracil after short systemic infusion: plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve.
    Port RE; Edler L; Herrmann R; Feldmann U
    Ther Drug Monit; 1991 Mar; 13(2):96-102. PubMed ID: 2053130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
    Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
    Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
    Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
    J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer.
    Turner PK; Houghton JA; Petak I; Tillman DM; Douglas L; Schwartzberg L; Billups CA; Panetta JC; Stewart CF
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):253-60. PubMed ID: 14648016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
    Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid.
    Jansman FG; Coenen JL; De Graaf JC; Tobi H; Sleijfer DT; Brouwers JR
    Anticancer Res; 2002; 22(6B):3449-55. PubMed ID: 12552938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites.
    Wang GP; Guan YS; Jin XR; Jiang SS; Lu ZJ; Wu Y; Li Y; Li M; Luo F
    J Gastroenterol Hepatol; 2010 May; 25(5):985-90. PubMed ID: 20546454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus.
    Gusella M; Ferrazzi E; Ferrari M; Padrini R
    Ther Drug Monit; 2002 Jun; 24(3):425-31. PubMed ID: 12021636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-performance liquid chromatographic assay of 5-fluorouracil in human erythrocytes, plasma and whole blood.
    Wattanatorn W; McLeod HL; Cassidy J; Kendle KE
    J Chromatogr B Biomed Sci Appl; 1997 Apr; 692(1):233-7. PubMed ID: 9187406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
    Büchel B; Rhyn P; Schürch S; Bühr C; Amstutz U; Largiadèr CR
    Biomed Chromatogr; 2013 Jan; 27(1):7-16. PubMed ID: 22454320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma.
    Kissel J; Brix G; Bellemann ME; Strauss LG; Dimitrakopoulou-Strauss A; Port R; Haberkorn U; Lorenz WJ
    Cancer Res; 1997 Aug; 57(16):3415-23. PubMed ID: 9270007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
    Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
    Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer.
    Mader RM; Steger GG; Rizovski B; Djavanmard MP; Scheithauer W; Jakesz R; Rainer H
    Br J Clin Pharmacol; 1995 Sep; 40(3):209-15. PubMed ID: 8527281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
    Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
    Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients.
    Wagner JG; Gyves JW; Stetson PL; Walker-Andrews SC; Wollner IS; Cochran MK; Ensminger WD
    Cancer Res; 1986 Mar; 46(3):1499-506. PubMed ID: 3943107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered plasma kinetics of 5-FU at high dosage in rat and man.
    Schwartz PM; Turek PJ; Hyde CM; Cadman EC; Handschumacher RE
    Cancer Treat Rep; 1985 Jan; 69(1):133-6. PubMed ID: 3967255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
    Gamelin E; Boisdron-Celle M; Guérin-Meyer V; Delva R; Lortholary A; Genevieve F; Larra F; Ifrah N; Robert J
    J Clin Oncol; 1999 Apr; 17(4):1105. PubMed ID: 10561167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.